TrialGynecologic oncology2012

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Russell J Schilder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.